葛兰素史克轮状病毒疫苗（RV1）的二十年：一项估计5岁以下儿童疫苗接种完成情况和避免死亡的全球分析

IF 4.8 3区医学 Q1 IMMUNOLOGY

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-09-25 DOI:10.1080/14760584.2025.2564167

Victoria Genovez, Olivia Berton, Stéphanie Barthès, Frederik Verelst, Eliana Biundo

{"title":"葛兰素史克轮状病毒疫苗（RV1）的二十年：一项估计5岁以下儿童疫苗接种完成情况和避免死亡的全球分析","authors":"Victoria Genovez, Olivia Berton, Stéphanie Barthès, Frederik Verelst, Eliana Biundo","doi":"10.1080/14760584.2025.2564167","DOIUrl":null,"url":null,"abstract":"Background: Rotavirus vaccination plays a key role in reducing rotavirus gastroenteritis (RVGE) related deaths. This analysis estimated the number of children under 5 years of age fully vaccinated with GSK rotavirus vaccine (RV1) since launch (2004) and its impact on RVGE-related deaths worldwide.Research design and methods: To estimate the number of children under 5 years fully vaccinated with RV1 since launch, we used unpublished RV1 market supply data from GSK. The data were extrapolated until the time point when 1 billion doses will have been supplied. The number of RVGE-related deaths avoided was calculated using previously published data on the number of children needed to be fully vaccinated to avoid one fatal RVGE.Results: Approximately 431 million children under 5 years received a complete RV1 course from 2004 to 2023, avoiding over 220,000 RVGE-related deaths globally. The forecasted analysis estimated that by January 2025, 1 billion RV1 doses will have been supplied worldwide, representing 239,000 RVGE-related deaths avoided. By December 2025, 0.5 billion babies will be protected with RV1, resulting in 259,000 RVGE-related deaths avoided since 2004.Conclusion: RV1 has contributed to reducing the number of RVGE cases and related deaths and is anticipated to continue reducing this disease burden.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"936-943"},"PeriodicalIF":4.8000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Two decades of GSK rotavirus vaccine (RV1): a global analysis to estimate vaccination completion and deaths averted in children under 5 years.\",\"authors\":\"Victoria Genovez, Olivia Berton, Stéphanie Barthès, Frederik Verelst, Eliana Biundo\",\"doi\":\"10.1080/14760584.2025.2564167\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Rotavirus vaccination plays a key role in reducing rotavirus gastroenteritis (RVGE) related deaths. This analysis estimated the number of children under 5 years of age fully vaccinated with GSK rotavirus vaccine (RV1) since launch (2004) and its impact on RVGE-related deaths worldwide.Research design and methods: To estimate the number of children under 5 years fully vaccinated with RV1 since launch, we used unpublished RV1 market supply data from GSK. The data were extrapolated until the time point when 1 billion doses will have been supplied. The number of RVGE-related deaths avoided was calculated using previously published data on the number of children needed to be fully vaccinated to avoid one fatal RVGE.Results: Approximately 431 million children under 5 years received a complete RV1 course from 2004 to 2023, avoiding over 220,000 RVGE-related deaths globally. The forecasted analysis estimated that by January 2025, 1 billion RV1 doses will have been supplied worldwide, representing 239,000 RVGE-related deaths avoided. By December 2025, 0.5 billion babies will be protected with RV1, resulting in 259,000 RVGE-related deaths avoided since 2004.Conclusion: RV1 has contributed to reducing the number of RVGE cases and related deaths and is anticipated to continue reducing this disease burden.\",\"PeriodicalId\":12326,\"journal\":{\"name\":\"Expert Review of Vaccines\",\"volume\":\" \",\"pages\":\"936-943\"},\"PeriodicalIF\":4.8000,\"publicationDate\":\"2025-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Review of Vaccines\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14760584.2025.2564167\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/9/25 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14760584.2025.2564167","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/25 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景：轮状病毒疫苗接种在减少轮状病毒胃肠炎（RVGE）相关死亡中起着关键作用。该分析估计了GSK轮状病毒疫苗（RV1）自2004年上市以来全面接种的5岁以下儿童数量，以及该疫苗对全球轮状病毒疫苗相关死亡的影响。研究设计和方法：为了估计自RV1上市以来5岁以下儿童完全接种的数量，我们使用了GSK未发表的RV1市场供应数据。这些数据是外推的，直到将提供10亿剂的时间点为止。避免的与RVGE相关的死亡人数是根据先前公布的关于需要充分接种疫苗以避免一次致命的RVGE的儿童人数的数据计算的。结果：从2004年到2023年，全球约有4.31亿5岁以下儿童接受了完整的RV1疗程，避免了超过22万例rvge相关死亡。预测分析估计，到2025年1月，全世界将提供10亿剂RV1疫苗，这意味着避免了23.9万例与rvge有关的死亡。到2025年12月，将有5亿婴儿得到RV1的保护，自2004年以来避免了25.9万例与rvge有关的死亡。结论：RV1有助于减少RVGE病例和相关死亡人数，预计将继续减少这种疾病负担。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Two decades of GSK rotavirus vaccine (RV1): a global analysis to estimate vaccination completion and deaths averted in children under 5 years.

Background: Rotavirus vaccination plays a key role in reducing rotavirus gastroenteritis (RVGE) related deaths. This analysis estimated the number of children under 5 years of age fully vaccinated with GSK rotavirus vaccine (RV1) since launch (2004) and its impact on RVGE-related deaths worldwide.

Research design and methods: To estimate the number of children under 5 years fully vaccinated with RV1 since launch, we used unpublished RV1 market supply data from GSK. The data were extrapolated until the time point when 1 billion doses will have been supplied. The number of RVGE-related deaths avoided was calculated using previously published data on the number of children needed to be fully vaccinated to avoid one fatal RVGE.

Results: Approximately 431 million children under 5 years received a complete RV1 course from 2004 to 2023, avoiding over 220,000 RVGE-related deaths globally. The forecasted analysis estimated that by January 2025, 1 billion RV1 doses will have been supplied worldwide, representing 239,000 RVGE-related deaths avoided. By December 2025, 0.5 billion babies will be protected with RV1, resulting in 259,000 RVGE-related deaths avoided since 2004.

Conclusion: RV1 has contributed to reducing the number of RVGE cases and related deaths and is anticipated to continue reducing this disease burden.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Expert Review of Vaccines 医学-免疫学

CiteScore

9.10

自引率

3.20%

发文量

136

审稿时长

4-8 weeks

期刊介绍： Expert Review of Vaccines (ISSN 1476-0584) provides expert commentary on the development, application, and clinical effectiveness of new vaccines. Coverage includes vaccine technology, vaccine adjuvants, prophylactic vaccines, therapeutic vaccines, AIDS vaccines and vaccines for defence against bioterrorism. All articles are subject to rigorous peer-review. The vaccine field has been transformed by recent technological advances, but there remain many challenges in the delivery of cost-effective, safe vaccines. Expert Review of Vaccines facilitates decision making to drive forward this exciting field.